相关实验视频

Updated: May 16, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

除癌症之外:基于CD47的治疗在非癌症疾病中的潜在应用

Wei-Qing Deng¹, Zi-Han Ye¹, Zhenghai Tang²

¹State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China.

Acta pharmaceutica Sinica. B

|April 3, 2025

概括

基于CD47的疗法显示出超越癌症的前景,通过调节免疫反应,有效治疗非癌症疾病. 对CD47点的进一步研究可能会为各种疾病开辟新的治疗途径.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

CD47作为"不要吃我"信号,在免疫检查点调节中至关重要.
基于CD47的抗癌疗法正在进行广泛的临床研究.
新出现的证据凸显了CD47治疗在非癌症疾病中的有效性.

研究的目的:

审查了解非癌症疾病的基于CD47的治疗的最新进展.
探索CD47在非癌症病理中的治疗机制.
确定CD47及其有约束力的合作伙伴的未来研究方向.

主要方法:

对非癌症疾病中基于CD47的治疗研究的文献综述.
对CD47调节的拟议作用机制的分析.
综合了关于CD47在循环,神经和消化系统中的作用的发现.

主要成果:

基于CD47的疗法在各种非癌症疾病中显示出治疗潜力.
机制包括调节细胞化,免疫细胞 (T细胞,树突细胞,中性粒细胞) 和细胞因子/化学因子分泌.
在了解CD47在全身炎症和自身免疫性疾病中的作用方面取得了重大进展.

结论:

基于CD47的药物为非癌症疾病提供了一个有前途的治疗策略.
针对CD47及其合作伙伴,为未来的药物开发提供了一个可行的方法.
需要进一步的研究,以充分阐明CD47在非瘤应用中的治疗潜力.

关键词:

申请申请表申请表 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 临床数据临床数据未来的展望未来的视角机理机制机理机制非癌症疾病非癌症疾病发细胞症 (phagocytosis) 是一种致死细胞的发生.临床前数据临床前数据

更多相关视频

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits

The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits

Published on: August 20, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cell-surface Signaling

Cell-surface Signaling

Hormones—or any molecule that binds to a receptor, known as a ligand—that are lipid-insoluble (water-soluble) are not able to diffuse across the cell membrane. In order to be able to affect a cell without entering it, these hormones bind to receptors on the cell membrane. When a first messenger, a hormone, binds to a receptor, a signal cascade is set off, causing second messengers, proteins inside the cell, to become activated, resulting in downstream effects.